Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Male Infertility Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for USP9Y drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | USP9Y Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for enzymatic and binding assays. |
View USP9Y Products |
| Gene Delivery | USP9Y Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View USP9Y Products |
| Benchmark Ab | Anti-USP9Y Recombinant Antibody Recombinant positive control for Western Blot, ELISA, and immunoprecipitation. |
View USP9Y Products |
| Validator | USP9Y siRNA Set Target-specific knockdown verification to confirm phenotype and target engagement. |
View USP9Y Products |
| Related Target A | USP9X Highly homologous X-linked counterpart. Crucial for selectivity and off-target counter-screening. |
View USP9X Products |
| Related Target B | MCL1 Downstream substrate stabilized by USP9X/Y deubiquitination. Key marker for apoptotic pathway modulation. |
View MCL1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Homology counter-screening (USP9X vs USP9Y) | Human USP9Y and USP9X ortholog proteins available with >95% purity and verified catalytic active domains. |
| Deubiquitinating (DUB) enzyme kinetics | Sequence-verified, endotoxin-controlled recombinant proteins with theoretical molecular weight confirmation. |
| Lack of Controls | Sequence-defined clinical benchmark antibodies and tool antibodies included. |
| False Positives in Knockdown | Validated siRNA sets included for target specificity and phenotype rescue checks. |
Live USP9Y R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ubiquitin-specific peptidase (USP) therapeutics is intensifying, with major players shifting focus from broad-spectrum proteasome inhibitors to selective deubiquitinating enzyme (DUB) targeting. USP9Y, encoded on the Y chromosome, has emerged as a critical node in male-specific cancers (such as prostate and colorectal cancers) and spermatogenesis regulation. As first-generation DUB inhibitors enter clinical evaluation, the next wave of R&D is targeting the strict discrimination between USP9Y and its highly homologous X-chromosome counterpart, USP9X, to minimize systemic toxicity and achieve tissue-specific therapeutic indexes.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | Prostate Cancer, Male Infertility, Colorectal Cancer | Selectivity Assay (Need High-Purity USP9Y vs USP9X Mutant/WT Proteins) |
| PROTACs / Degraders | Targeted Protein Degradation (TPD) Developers | Refractory Solid Tumors, Hematological Malignancies | Ternary Complex Validation (Need Sequence-Verified USP9Y Recombinant Protein) |
| RNA Therapeutics (siRNA) | Oligonucleotide Therapeutics Developers | Oncological Overexpression Phenotypes | In vitro Knockdown Validation (Need Validated USP9Y siRNA Sets) |